Literature DB >> 21058726

Identification of the spiro(oxindole-3,3'-thiazolidine)-based derivatives as potential p53 activity modulators.

Isabel Gomez-Monterrey1, Alessia Bertamino, Amalia Porta, Alfonso Carotenuto, Simona Musella, Claudio Aquino, Ilaria Granata, Marina Sala, Diego Brancaccio, Delia Picone, Carmine Ercole, Paola Stiuso, Pietro Campiglia, Paolo Grieco, Pio Ianelli, Bruno Maresca, Ettore Novellino.   

Abstract

Here, we report the design of new analogues of spirooxoindolepyrrolidine nucleus as modulators of p53 activity. Compounds (3R,7aR)-6-(4-chlorobenzyl)-1H-spiro[imidazo[1,5-c]thiazole-3,3'-indoline]-2',5,7(6H,7aH)-trione (9c) and (3R,7aR)-5'-methyl-6-(3,4,5-trimethoxybenzyl)-1H-spiro[imidazo[1,5-c]thiazole-3,3'-indoline]-2',5,7(6H,7aH)-trione (10d) are the most potent compounds of this series, inhibiting cell growth of different human tumor cells at submicromolar and micromolar concentrations, respectively. Compound 9c induces apoptotic cell death in human melanoma cell line M14 at 24 h, while in the same condition, treatment with 10d showes a clear arrest at G2/M phase inducing delay of cell cycle progression. Possibly, these activities may be due to inhibition of p53-MDM2 interaction and subsequent p53 release and activation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21058726     DOI: 10.1021/jm100838z

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

Review 1.  Molecular diversity of spirooxindoles. Synthesis and biological activity.

Authors:  Tetyana L Pavlovska; Ruslan Gr Redkin; Victoria V Lipson; Dmytro V Atamanuk
Journal:  Mol Divers       Date:  2015-09-29       Impact factor: 2.943

2.  A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.

Authors:  Yujun Zhao; Shanghai Yu; Wei Sun; Liu Liu; Jianfeng Lu; Donna McEachern; Sanjeev Shargary; Denzil Bernard; Xiaoqin Li; Ting Zhao; Peng Zou; Duxin Sun; Shaomeng Wang
Journal:  J Med Chem       Date:  2013-06-20       Impact factor: 7.446

Review 3.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.

Authors:  Yujun Zhao; Angelo Aguilar; Denzil Bernard; Shaomeng Wang
Journal:  J Med Chem       Date:  2014-11-14       Impact factor: 7.446

4.  New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53.

Authors:  D Sorriento; C Del Giudice; A Bertamino; M Ciccarelli; I Gomez-Monterrey; P Campiglia; E Novellino; M Illario; B Trimarco; N De Luca; G Iaccarino
Journal:  Br J Cancer       Date:  2014-11-25       Impact factor: 7.640

5.  Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.

Authors:  Simona Daniele; Barbara Costa; Elisa Zappelli; Eleonora Da Pozzo; Simona Sestito; Giulia Nesi; Pietro Campiglia; Luciana Marinelli; Ettore Novellino; Simona Rapposelli; Claudia Martini
Journal:  Sci Rep       Date:  2015-04-21       Impact factor: 4.379

6.  Redox-neutral α-sulfenylation of secondary amines: ring-fused N,S-acetals.

Authors:  Claire L Jarvis; Matthew T Richers; Martin Breugst; K N Houk; Daniel Seidel
Journal:  Org Lett       Date:  2014-06-13       Impact factor: 6.005

7.  p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis.

Authors:  Rubeta N Matin; Anissa Chikh; Stephanie Law Pak Chong; David Mesher; Manuela Graf; Paolo Sanza'; Valentina Senatore; Maria Scatolini; Francesca Moretti; Irene M Leigh; Charlotte M Proby; Antonio Costanzo; Giovanna Chiorino; Rino Cerio; Catherine A Harwood; Daniele Bergamaschi
Journal:  J Exp Med       Date:  2013-02-18       Impact factor: 14.307

8.  Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.

Authors:  Barbara Costa; Sara Bendinelli; Pamela Gabelloni; Eleonora Da Pozzo; Simona Daniele; Fabrizio Scatena; Renato Vanacore; Pietro Campiglia; Alessia Bertamino; Isabel Gomez-Monterrey; Daniela Sorriento; Carmine Del Giudice; Guido Iaccarino; Ettore Novellino; Claudia Martini
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

Review 9.  Chemical Variations on the p53 Reactivation Theme.

Authors:  Carlos J A Ribeiro; Cecília M P Rodrigues; Rui Moreira; Maria M M Santos
Journal:  Pharmaceuticals (Basel)       Date:  2016-05-13

10.  Targeted Synthesis of Complex Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-ones by Intramolecular Cyclization of Azomethine Ylides: Highly Potent MDM2-p53 Inhibitors.

Authors:  Andreas Gollner; Harald Weinstabl; Julian E Fuchs; Dorothea Rudolph; Geraldine Garavel; Karin S Hofbauer; Jale Karolyi-Oezguer; Gerhard Gmaschitz; Wolfgang Hela; Nina Kerres; Elisabeth Grondal; Patrick Werni; Juergen Ramharter; Joachim Broeker; Darryl B McConnell
Journal:  ChemMedChem       Date:  2018-12-11       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.